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MaBACKGROUND Children with cardiomyopathy (CM) are at risk of sudden cardiac death (SCD), but the incidence and risk
factors for this outcome are not clear.
OBJECTIVES This study sought to determine the incidence and risk factors for SCD in children with varying CM phe-
notypes from a long-term population-based study of childhood CM.
METHODS The NACCS (National Australian Childhood Cardiomyopathy Study) is an ongoing longitudinal cohort study
including all children in Australia with primary CM who were diagnosed between January 1, 1987, and December 31, 1996,
and were <10 years of age. The cumulative incidence and risk factors for SCD within individual CM phenotypes were
explored using survival analysis.
RESULTS Of 289 eligible patients, 16 (5.5%) experienced SCD over a median follow-up of 11.9 years (interquartile
range: 1.7 to 15.4). The risk of SCD varied according to CM phenotype (p ¼ 0.007). The cumulative incidence of SCD at
15 years was 5% for dilated cardiomyopathy (DCM), 6% for hypertrophic cardiomyopathy (HCM), 12% for restrictive
cardiomyopathy, and 23% for left ventricular (LV) noncompaction. Older age at diagnosis, positive family history of CM,
and severity of LV dysfunction were related to increased risk of SCD in patients with DCM, and a higher posterior wall
thickness Z-score was the sole risk factor identiﬁed for patients with HCM.
CONCLUSIONS Predictors of SCD include CM phenotype, family history of CM (DCM), severity of systolic dysfunction
(DCM), and extent of LV hypertrophy (HCM). Continuing follow-up of this cohort into adulthood is likely to reveal an
ongoing risk of SCD. (J Am Coll Cardiol 2015;65:2302–10) © 2015 by the American College of Cardiology Foundation.P ediatric cardiomyopathies (CMs) are an un-common and heterogeneous group of con-ditions, with multiple etiologies and varied
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AB BR E V I A T I O N S
AND ACRONYM S
CHF = congestive heart failure
CM = cardiomyopathy
DCM = dilated cardiomyopathy
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2303incidence and risk factors for SCD in children with
varying CM phenotypes have not previously been
well deﬁned (4–7). Better data regarding the inci-
dence and risk factors for SCD in this population are
required to deploy appropriate primary prevention
strategies targeting high-risk individuals.SEE PAGE 2311
HCM = hypertrophic
cardiomyopathy
ICD = implantable
cardioverter-deﬁbrillator
LVEDD = left ventricular
end-diastolic dimension
LVFS = left ventricular
fractional shortening
LVNC = left ventricular
noncompaction
RCM = restrictive
cardiomyopathy
SCD = sudden cardiac deathThe NACCS (National Australian Childhood Car-
diomyopathy Study) is a population-based cohort
study comprising all Australian children under the
age of 10 years who were diagnosed with CM over a
10-year period (8). Using this cohort, we sought to
describe the incidence of SCD in young children with
different CM phenotypes and to explore risk factors
for SCD in this population.
METHODS
STUDY DESIGN. The NACCS is an ongoing cohort
study that includes all children in Australia with pri-
mary CM who were diagnosed between January 1,
1987, and December 31, 1996, and were younger than
10 years of age at diagnosis. The exclusion criteria
included congenital heart disease, arrhythmia-
induced cardiac dysfunction, Kawasaki disease,
prior exposure to corticosteroids or anthracyclines,
progressive systemic, metabolic, or neuromuscular
disease resulting in other severe organ involvement,
and maternal diabetes or prematurity for children
who were diagnosed before 4 weeks of age. Full de-
tails of the methods, including enrollment and in-
clusion and exclusion criteria, have been detailed
elsewhere (8). Local ethics committee approval was
obtained in accordance with requirements from each
participating center.
DATA COLLECTION. Prospective follow-up was ar-
ranged for enrolled study patients, using standard-
ized data collection sheets to document uniform
clinical and echocardiographic data at baseline and
throughout follow-up. Echocardiographic measure-
ments were normalized according to body surface
area or age (9). The variables recorded for each
patient are listed in the Online Appendix.
CLASSIFICATION OF CASES. A single observer
assigned each case to a diagnostic category according
to theWorld Health Organization’s classiﬁcation of CM
(10) during site visits, after directly reviewing each
medical record and all available data, including
diagnostic cardiac imaging. The diagnostic criteria
for dilated cardiomyopathy (DCM), hypertrophic
cardiomyopathy (HCM), restrictive cardiomyopathy
(RCM) and left ventricular noncompaction (LVNC)
have previously been described (8). Patients wereexcluded from this analysis if they did not
clearly meet the criteria for 1 of these 4 CM
phenotypes. A single pediatric pathologist
centrally reviewed all available cardiac his-
tology and made a diagnosis of lymphocytic
myocarditis on the basis of the Dallas criteria
(11). The diagnosis of familial CM required a
history of at least 1 affected ﬁrst- or second-
degree relative. SCD was deﬁned as a sudden
and unexpected death in a child within 4 h of
new symptoms and was adjudicated by the
same observer who reviewed each medical
record. Congestive heart failure (CHF) was
assessed on the basis of signs and symptoms
recorded by the attending physician. Patients
who died following abrupt deterioration in
the setting of CHF or during hospitalization for
heart failure management were considered to
have died of CHF.
STATISTICAL METHODS. The cumulative incidence
of SCD for each CM phenotype was assessed using
survival analysis. Patients who died of other causes
were censored at the time of death, and patients who
are still alive were censored at the time of last follow-
up. Patients who were not known to have CM until
they experienced SCD and those who died within 24 h
of diagnosis were excluded from the survival analysis
because pre-death data were not available for this
group. In patients with DCM, normalization of
LV function was considered to have occurred on the
ﬁrst occasion when the left ventricular end-diastolic
dimension (LVEDD) Z-score was <þ2.0 and the left
ventricular fractional shortening (LVFS) Z-score was
>2.0. Because implantable cardioverter-deﬁbrillator
(ICD) insertion may have modiﬁed the risk of SCD, a
competing risk analysis was performed, with results
presented as cumulative incidence of SCD, heart
failure death/transplant, and ICD insertion, along
with the corresponding survival curve.
Risk factors for SCD for each CM phenotype were
assessed using Cox proportional hazards models. Pa-
tients who experienced either of the competing risks
of heart failure death/transplant or ICD insertion were
censored at the time of the event. Patients were
censored at the time of last follow-up if no event was
experienced. Potential risk factors (Online Appendix)
included characteristics at the time of diagnosis, as
well as the latest and rate of change of echocardio-
graphic measurements (included as time-dependent
covariates, for which rate of change was the differ-
ence between the 2 most recent measurements before
the event divided by the time between the measure-
ments). Echocardiographic measurements considered
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interventricular septal thickness Z-scores. Risk fac-
tors were considered in univariable models to assess
independent predictors. In view of the low event
rates for SCD, multivariable analysis was not
undertaken.
RESULTS
A total of 301 patients with a CM phenotype of DCM,
HCM, RCM, or LVNC were recruited into the NACCS
between January 1, 1987, and December 31, 1996. Nine
patients with DCM had SCD as their ﬁrst manifesta-
tion, and an additional 3 patients with DCM died
within 24 h of diagnosis, leaving 289 for this analysis.
The demographics of the study population are shown
in Table 1. The majority of patients were diagnosed
with CM during their ﬁrst year of life (median age at
diagnosis for all patients 0.56 years; interquartile
range [IQR]: 0.15 to 1.91 years). Follow-up data were
available for all patients. The median duration of
follow-up was 11.9 years (IQR: 1.7 to 15.4 years) for all
patients and 14.2 years (IQR: 12.5 to 17.4 years) for
those who survived without transplantation. Nine-
teen percent of the cohort (n ¼ 55) had familial CM.
INCIDENCE OF SCD. SCD occurred in 16 patients
(Table 1). SCD accounted for 15% of all deaths in the
study cohort and 24% of deaths among patients
who died >1 year after diagnosis.
The cumulative incidence of SCD at 15 years after
diagnosis (Central Illustration) was 5% (95% CI: 2% to
11%) for DCM, 6% (95% CI: 2% to 17%) for HCM, 23%
(95% CI: 10% to 47%) for LVNC, and 12% (95% CI: 2%
to 61%) for RCM (p ¼ 0.007 for association of inci-
dence and CM phenotype). The median LVEDD
Z-score at the latest follow-up in patients with DCM
who experienced SCD was þ5.3 (range 4.2 to 8.6),
and the median LVFS Z-score was 9.5 (range 13.0TABLE 1 Demographics of Study Population
DCM
(n ¼ 172)
HCM
(n ¼ 80)
Age at diagnosis, yrs 0.65 (0.16–1.69) 0.45 (0.12–2.48
Follow-up, yrs 12.5 (0.6–15.9) 14.0 (10.7–17.1
Follow-up for survivors, yrs* 15.1 (13.0–17.3) 15.7 (12.9–17.7
Positive family history of CM 26 (13.4) 19 (23.8)
Outcome
SCD 6 4
HFD/transplant 62 13
Survivors 104 63
Values are median (IQR), n (%), or n. *Patients surviving without heart transplant.
CM ¼ cardiomyopathy; DCM ¼ dilated cardiomyopathy; HCM ¼ hypertrophic cardiomy
noncompaction; N/A ¼ not applicable; RCM ¼ restrictive cardiomyopathy; SCD ¼ suddeto 6.2). There were no instances of SCD among
those who had documented echocardiographic nor-
malization of LV function. The median age at SCD was
8.6 years (ages of individual patients 1.5, 5.1, 6.9,
10.2, 11.2, and 15.2 years) for patients with DCM,
8.3 years (ages of individual patients 0.5, 7.1, 9.5, and
14.0 years) for HCM, 2.8 years (ages of individual
patients 0.9, 2.6, 3.0, 3.1, and 3.3 years) for LVNC, and
2.8 years for the patient with RCM.
Figure 1 shows a breakdown of the outcomes by
CM phenotype presented as competing risk curves.
These indicate an ongoing risk of SCD beyond the
ﬁrst few years after diagnosis, especially for patients
with DCM or HCM.
FAMILIAL CM. There were 55 patients with familial
CM: 26 with DCM, 19 with HCM, 9 with LVNC, and 1
with RCM. Of these patients, 3 with DCM and 2 with
LVNC experienced SCD. None of the 9 patients with
familial HCM or the single patient with familial RCM
died suddenly.
DEVICE THERAPY. During the study period, ICD
insertion was performed in 19 patients (4 DCM, 13
HCM, and 2 LVNC): in 9 patients for primary pre-
vention and in the remaining 10 due to syncopal
symptoms or documented arrhythmias. During a
7.8  4.5 years after ICD insertion, 1 patient with DCM
died suddenly and the remaining 18 patients are
alive. Appropriate deﬁbrillator shocks were docu-
mented in 5 of 14 patients (35.7%) for whom this
information was available. No cardiac resynchroni-
zation therapy devices have been implanted into any
of the study patients.
RISK FACTORS FOR SCD IN DCM. Older age at diag-
nosis, presence of familial CM, and lower LVFS
Z-score at the latest follow-up were associated with
increased risk of SCD in patients with DCM (Table 2).
A higher LVEDD Z-score was also associated withLVNC
(n ¼ 29)
RCM
(n ¼ 8)
All Patients
(N ¼ 289)
) 0.34 (0.10–1.33) 3.03 (2.59–5.44) 0.56 (0.15–1.91)
) 6.8 (7.0–14.1) 2.8 (1.5–7.2) 11.9 (1.7–15.4)
) 14.3 (12.2–14.7) N/A (n ¼ 1) 14.2 (12.5–17.4)
9 (3.4) 1 (12.5) 55 (19.0)
5 1 16
11 6 92
13 1 181
opathy; HFD ¼ heart failure death; IQR ¼ interquartile range; LVNC ¼ left ventricular
n cardiac death.
FIGURE 1 Outcomes for Patients With CM
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Cumulative incidence for the competing risks of sudden cardiac death (SCD), death due to congestive heart failure (CHF) or transplantation, and
implantable cardioverter-deﬁbrillator (ICD) insertion. Event-free survival in patients with dilated cardiomyopathy (A), hypertrophic cardio-
myopathy (B), left ventricular noncompaction (C), and restrictive cardiomyopathy (D).
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2305increased risk of SCD but not in addition to LVFS
Z-score. There were no patients with lymphocytic
myocarditis diagnosed by endomyocardial biopsy
who experienced SCD during the study follow-up,
although lymphocytic myocarditis was found in 6
of 9 excluded patients whose initial symptom was
sudden death.
RISK FACTORS FOR SCD IN HCM. The only variable
that was identiﬁed as a predictor of SCD in patients
with HCM was the LV posterior wall thickness
Z-score at the latest follow-up (Table 3). The pres-
ence of familial HCM could also have been protective
of SCD, but the magnitude of any effect could not
be assessed because no one with familial HCM died
suddenly.
RISK FACTORS FOR SCD IN LVNC. There was a trend
toward a higher risk of SCD in patients with LVNC
with deteriorating ventricular function measured by
LVFS or LVEDD and greater severity of LVNC as
measured by increased ratio of compacted to non-
compacted myocardium (Table 4).RISK FACTORS FOR SCD IN RCM. It was not possible
to explore risk factors for SCD in patients with RCM
because there was only 1 instance of SCD.
DISCUSSION
This national, population-based cohort study is
unique because of its fully inclusive nature, the
extended follow-up duration, and the availability of
comparative data for different CM phenotypes. This
study provided insight into the incidence of SCD in
children with CM and identiﬁed potential predictors
for this outcome. As seen in this study, SCD is an
important cause of mortality, affecting between 5%
and 25% of patients over a 15-year period according to
CM phenotype (Central Illustration). These estimates
are conservative due to the stringent deﬁnition of
SCD and the exclusion of patients who deteriorated
abruptly in the setting of CHF.
The identiﬁcation of patients with CM who are at
risk of SCD may facilitate modiﬁcation of the natural
history by allowing the clinician to target high-risk
TABLE 3 Risk Factor
Sex (female vs. male)
Race (Aboriginal vs. ot
Age at diagnosis, yrs
Congestive heart failur
Family history of CM
Family history of CM w
Noonan syndrome
Latest end-diastolic dim
Latest fractional shorte
Latest posterior wall th
Latest interventricular
Rate of change of end-
Rate of change of fract
Rate of change of post
Rate of change of inter
*Not possible to calculate
Abbreviations as in Tabl
TABLE 2 Risk Factors for SCD in Patients With DCM
Univariable Analysis
HR (95% CI) p Value
Sex (female vs. male) 0.41 (0.07–2.21) 0.30
Race (Aboriginal vs. other) *
Age at diagnosis, yrs 1.40 (1.11–1.77) 0.005
Congestive heart failure at diagnosis *
Family history of CM 7.19 (1.44–35.9) 0.02
Family history of CM with sudden death *
Myocarditis †
Latest end-diastolic dimension Z-score 1.61 (1.16–2.22) 0.004
Latest fractional shortening Z-score 0.75 (0.60–0.93) 0.009
Rate of change of end-diastolic dimension Z-score (per year) 1.01 (0.91–1.12) 0.87
Rate of change of fractional shortening Z-score (per year) 0.73 (0.49–1.07) 0.10
*Not possible to calculate an HR because all 6 events occurred in 1 category. †Not possible to calculate an HR
because there were no SCD events in patients with biopsy-proven myocarditis.
HR ¼ hazard ratio; other abbreviations as in Table 1.
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2306patients for insertion of ICDs. These have proven
efﬁcacy in preventing SCD by terminating life-
threatening ventricular arrhythmias in children and
adolescents identiﬁed to be at high risk (12).
DILATED CM. Children with DCM make up the largest
proportion of this cohort (59.5%) and have a lower
incidence of SCD than children with other CM phe-
notypes. Late normalization of LV function has been
noted in a high proportion of children with DCM (13)
and may account for the generally lower rates of
SCD in this CM phenotype.
In the current study, familial CM was an important
risk factor for SCD in patients with DCM, a phenom-
enon that could potentially be explained by thes for SCD in Patients With HCM
Univariable Risk Factors
HR (95% CI) p Value
2.29 (16.31–0.32) 0.41
her) *
0.68 (1.62–0.28) 0.38
e at diagnosis *
*
ith sudden death *
1.38 (2.65–0.72) 0.34
ension Z-score 1.13 (1.73–0.74) 0.56
ning Z-score 1.00 (1.29–0.77) 0.98
ickness Z-score 1.47 (2.03–1.06) 0.02
septal thickness Z-score 1.05 (1.49–0.73) 0.81
diastolic dimension Z-score (per year) 0.90 (1.37–0.59) 0.62
ional shortening Z-score (per year) 1.03 (1.51–0.70) 0.89
erior wall thickness Z-score (per year) 1.01 (1.31–0.78) 0.94
ventricular septal thickness Z-score (per year) 0.93 (1.96–0.44) 0.85
an HR because all events occurred in 1 category.
es 1 and 2.presence of familial proarrhythmic genotypes (14,15).
This ﬁnding is in contrast to a report from the PCMR
(Pediatric Cardiomyopathy Registry), in which family
history was not associated with SCD (16). In the PCMR
study, sex, ethnicity, and etiology were also not
associated with SCD, as in our study, and greater LV
dilation, age at diagnosis <14.3 years, and lower LV
posterior wall thickness to LVEDD ratio were predic-
tive of SCD. The difference with respect to familial
DCM between these 2 studies may be explained by the
age difference of enrolled patients, the more severe
presentation of familial DCM in our younger patients,
and our exclusion criteria. In the NACCS registry,
familial DCM was also associated with a higher risk
of death or transplantation during follow-up (13).
In children with DCM, the highest risk of death or
transplantation occurs in the ﬁrst year after diagnosis
(13). The risk of SCD, on the other hand, appears to
be ongoing in individuals with persisting cardiac
dysfunction. The association between severity of LV
dysfunction and the risk of SCD is supported by studies
in children and adults (5,17) and is consistent with ob-
servations from multiple studies showing that worse
systolic function at diagnosis is associated with gener-
ally poorer short- and long-term outcomes (2,4,13).
In the present study, there were no patients with
myocarditis who experienced SCD. A recent report
from the PCMR study demonstrated that children
with DCM secondary to biopsy-proven or clinically
diagnosed myocarditis had generally better outcomes,
with lower rates of both death and transplantation,
and higher rates of normalization of ventricular func-
tion (18).
HYPERTROPHIC CM. Pediatric HCM is characterized
by a variety of metabolic, mitochondrial, and sarco-
meric etiologies, some of which are not fully
expressed until adult life. Risk factors for SCD in HCM
previously reported in adult patients include family
history of SCD, documented ventricular arrhythmias,
and abnormal blood pressure response during exer-
cise (19–21). Maron et al. (22,23) also found that
approximately 40% of patients with HCM who die
suddenly do so during, or just after, exertion. How-
ever, approximately 60% experience SCD while they
are inactive or mildly active (24), with the majority
being symptom free beforehand. Several studies have
shown that severely increased LV wall thickness is an
important marker of risk for SCD (25–27). In our study,
the most important risk factor for SCD in patients
with HCM was the magnitude of LV free wall hyper-
trophy. The potential protective effect of familial
HCM in our cohort of pediatric patients may explain
why isolated septal hypertrophy, typically associated
TABLE 4 Risk Factors for SCD in Patients With LVNC
Univariable Analysis
HR (95% CI) p Value
Sex (female vs. male) 0.89 (8.20–0.10) 0.92
Race (Aboriginal vs. other) *
Age at diagnosis, yrs 0.94 (1.83–0.48) 0.85
Congestive heart failure at diagnosis 0.49 (2.92–0.08) 0.43
Family history of cardiomyopathy 0.89 (5.40–0.15) 0.90
Family history of sudden death 2.25 (20.29–0.25) 0.47
End-diastolic dimension Z-score 0.85 (1.22–0.59) 0.37
Fractional shortening Z-score 0.91 (1.16–0.71) 0.44
Rate of change of end-diastolic dimension Z-score (per year) 1.64 (2.92–0.92) 0.09
Rate of change of fractional shortening Z-score (per year) 1.10 (1.24–0.98) 0.11
Ratio of compacted to noncompacted myocardium
Systole 3.89 (29.43–0.51) 0.19
Diastole 2.90 (9.68–0.87) 0.08
*Not possible to calculate an HR because all events occurred in 1 category.
Abbreviations as in Tables 1 and 2.
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creased risk of SCD.
Family history of SCD in the setting of familial HCM
has been suggested as a risk factor for SCD, particu-
larly in association with syncope (28–30). Certain
sarcomeric mutations are associated with higher-risk
phenotypes (31,32). In our study, no patients with
familial HCM died suddenly, although it is unlikely
that these patients were truly protected from the risk
of this outcome. These individuals may not yet have
reached full phenotypic expression of the disease and
may therefore remain at ongoing risk of SCD during
adult life.
LV NONCOMPACTION. Other than the diagnosis
itself, we were unable to identify individual risk fac-
tors for SCD in patients with LVNC. This disease is
uncommon and has multiple subtypes; the small
number of patients in our study may have limited our
ability to quantify and detect risk factors for SCD.
These patients have a variable, but generally poor,
outcome overall, as has also been noted by other re-
searchers (33,34). In a large study of 240 patients
with LVNC (34), the risk of SCD was found to be
6%, compared with 23% in the present study. The
unexpectedly high incidence of SCD in patients with
LVNC may reﬂect the early onset of severe DCM
physiology in our study. Children with LVNC have a
high incidence of arrhythmias, and in the presence
of ventricular dysfunction, they should be considered
at risk of SCD (34).
RESTRICTIVE CM. We were unable to explore risk
factors for SCD in RCM due to the small number of
events in this population-based study; however, as
suggested here and in previous studies, children with
RCM have poor survival rates (35–37). In a reported
series of 18 children with RCM, 5 (28%) experienced
“sudden death events”; 1 of these children was suc-
cessfully resuscitated and proceeded to transplant
and 4 died (38). Our ﬁgures are in accord with this;
although the absolute number of patients was small,
the incidence rate of death was large. A high pro-
portion of our patients with RCM underwent trans-
plant; because there is no effective therapy for RCM,
transplantation is the only therapeutic option that
decreases mortality (39).
TIMING OF SUDDEN DEATH. In both LVNC and
RCM, patients in our series experienced SCD relatively
early; all SCDs in these 2 diagnostic groups occurred
within the ﬁrst 3 years following diagnosis. Con-
versely, patients with DCM or HCM have an ongoing
risk, with a gradual increase in the cumulative inci-
dence of SCD continuing many years after diagnosis
and commencement of heart failure therapy.ICD THERAPY. Long-term follow-up data on children
with ICDs are lacking, and it has not yet been precisely
established which subgroup of children with CM
warrants primary prevention of SCD with implantable
deﬁbrillators or at which age implantation is appro-
priate. Complications related to ICD leads remain a
major problem in pediatric patients (40). A recent
study that examined a mixed group of children and
adults with HCM considered at high risk of SCD with
ICDs inserted as primary prevention found no overall
association between age of implantation and subse-
quent risk of appropriate ICD discharge (41). ICD
discharge and SCD remain signiﬁcant risks, even in
the presence of antiarrhythmic drug therapy (41–43).
An unwanted complication of ICDs are inappro-
priate discharges, which are not uncommon in many
reported series, being approximately 25% (41). Inap-
propriate shocks have been reported to be more
common in younger patients (<30 years of age)
(41,44). Only 1 of our study patients who received an
ICD subsequently died, and none has been listed for
heart transplant. However, uniform implantation of
ICDs for primary prevention of SCD in pediatric
patients awaiting transplant has been shown to be
unlikely to improve survival (45).
Despite detailed guidelines (46) for adult patients,
there is a lack of evidence-based guidelines for pe-
diatric patients, and decisions to implant an ICD in a
child are frequently difﬁcult, with multiple individual
considerations. The risk factors for SCD identiﬁed
in this pediatric population may ﬁnd a place in
decision-making with regard to primary prevention
in conjunction with traditional risk factors derived
from adult studies.
CENTRAL ILLUSTRATION Sudden Death in Childhood Cardiomyopathy: Cumulative Incidence by
Cardiomyopathy Phenotype
Bharucha, T. et al. J Am Coll Cardiol. 2015; 65(21):2302–10.
This graph shows the cumulative incidence of sudden cardiac death (SCD) by cardiomyopathy (CM) phenotype in children to 15 years from
diagnosis. The incidence of SCD varied by CM type, with patients with left ventricular noncompaction (LVNC) being at highest risk. Patients
withdilated cardiomyopathy (DCM)orhypertrophic cardiomyopathy (HCM) experience anongoing risk of SCD.RCM¼ restrictive cardiomyopathy.
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2308STUDY LIMITATIONS. An important limitation in this
study was the relatively small number of children
with SCD, particularly within the less common CM
phenotypes, which limits analysis of potential risk
factors, including CM etiology, and precludes multi-
variable analysis.
One could argue that our study may underestimate
the incidence of SCD, in large part due to our very
stringent deﬁnition of SCD. Cardiac transplant may have
improved outcomes for some study patients and
thereby masked their risk of SCD. However, the majority
of patients who underwent transplant had signs and
symptoms of CHF and would therefore not have quali-
ﬁed for the deﬁnition of SCD we used in this study. In
addition, despite our long follow-up duration, patients
with HCM may not have entered their highest risk
period, which is likely to be in early adult life (19).
This study was not designed to test the efﬁcacy
of heart failure therapy for SCD prevention. Medical
therapy and indication for ICD insertion were at the
discretion of individual physicians, leading to a wide
heterogeneity in therapy and interventions across the
cohort. Given this heterogeneity, we are unable to
comment on the protective effect of individual medical
therapies. Across the country, there was not uniformity
in investigations performed at follow-up; in particular,exercise stress testing and ambulatory electrocardio-
gram monitoring were not available for all patients with
HCM. Traditional risk factors for SCD in adult patients
with HCM could therefore not be examined.
CONCLUSIONS
This national population-based study encompassing
all Australian children with CM over a 10-year period,
with a long duration of follow-up, provided unique
insights into the comparative incidence of SCD in
children with different CM phenotypes and identiﬁed
predictors of this potentially preventable catastrophic
outcome. Further corroboration in larger childhood
studies of individual CM phenotypes will ultimately
facilitate optimal management strategies by clari-
fying which patients are at greatest risk of SCD and
might beneﬁt from primary prevention ICD therapy.
Continuing follow-up of this cohort into adulthood
is likely to reveal an ongoing risk of SCD in this
population.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: CM are
at variable risk of sudden death related to CM pheno-
type. In those with dilated CM, a family history of
dilated CM and more severe left ventricular dysfunction
are risk factors for sudden death, whereas among those
with hypertrophic CM, posterior wall thickness is a
risk factor.
TRANSLATIONAL OUTLOOK: Further research
involving larger cohorts is needed to enhance risk strati-
ﬁcation and guide more effective targeting of strategies
to prevent arrhythmic death.
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